https://www.hoparx.org/2026-04-02https://www.hoparx.org/about-us/2025-04-24https://www.hoparx.org/about-us/history/2025-03-26https://www.hoparx.org/about-us/history/hematology-oncology-pharmacy-timeline/2025-03-26https://www.hoparx.org/about-us/leadership/2026-03-30https://www.hoparx.org/about-us/leadership/heidi-finnes/2023-08-29https://www.hoparx.org/about-us/leadership/larry-w-buie-pharmd-bcop-fashp/2023-10-18https://www.hoparx.org/about-us/leadership/amy-seung-pharmd-bcop-fhopa/2026-03-30https://www.hoparx.org/about-us/leadership/amber-lawson-pharmd-bcop/2023-08-29https://www.hoparx.org/about-us/leadership/lisa-e-davis-pharmd-bcop-bcps-fccp/2023-08-29https://www.hoparx.org/about-us/leadership/shannon-hough-pharmd-bcop/2024-05-20https://www.hoparx.org/about-us/leadership/anne-krolikowski-cae/2023-08-29https://www.hoparx.org/about-us/leadership/jolynn-sessions-pharmd-bcop-fhopa/2024-05-20https://www.hoparx.org/about-us/leadership/jason-bergsbaken-pharmd-bcop-mba/2026-03-30https://www.hoparx.org/about-us/leadership/sol-atienza-pharmd-bcop/2025-06-11https://www.hoparx.org/about-us/leadership/sara-scott/2023-10-12https://www.hoparx.org/about-us/leadership/jennifer-murphy/2023-10-12https://www.hoparx.org/about-us/leadership/robert-mancini-bio/2026-03-30https://www.hoparx.org/about-us/leadership/zahra-mahmoudjafari-pharmd-mba-bcop-fhopa/2026-03-11https://www.hoparx.org/about-us/leadership/kamakshi-rao-pharmd-bcop-fhopa/2026-03-30https://www.hoparx.org/about-us/leadership/philip-schwieterman-pharmd-mha/2026-03-23https://www.hoparx.org/about-us/leadership/katie-gatwood-pharmd-bcop/2025-06-11https://www.hoparx.org/about-us/leadership/chelsea-gustafson-bio/2026-03-30https://www.hoparx.org/about-us/leadership/ila-m-saunders-bio/2026-03-30https://www.hoparx.org/about-us/volunteer-groups-index/2026-03-18https://www.hoparx.org/about-us/advocacy-awareness/2025-01-24https://www.hoparx.org/about-us/advocacy-awareness/activities/2026-03-10https://www.hoparx.org/about-us/advocacy-awareness/activities/hopa-hill-day/2026-03-10https://www.hoparx.org/about-us/advocacy-awareness/activities/drug-shortages-webinar/2023-07-07https://www.hoparx.org/about-us/advocacy-awareness/get-involved/2025-06-24https://www.hoparx.org/about-us/advocacy-awareness/public-policy-agenda/2023-02-01https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/2026-01-30https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/lauren-bendesky/2026-02-10https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/sandra-zori/2025-07-22https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/judith-smith/2025-07-22https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/kathleen-sellick/2025-07-22https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/kathryn-redden/2025-07-22https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/melinda-corley/2025-07-22https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/manpreet-chahal/2025-07-22https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/jim-murphy/2025-07-22https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/stephanie-anderson/2025-07-22https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/susan-king/2025-07-22https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/sara-kim/2025-07-28https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/leanne-kennedy/2025-07-22https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/lisa-dutton/2026-01-30https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/maria-lanza/2026-01-30https://www.hoparx.org/about-us/advocacy-awareness/patient-outreach/tim-mcdonald/2026-01-30https://www.hoparx.org/about-us/advocacy-awareness/legislative-action-center/2025-06-24https://www.hoparx.org/about-us/access-representation-opportunity-at-hopa/2025-08-13https://www.hoparx.org/about-us/access-representation-opportunity-at-hopa/aro-toolkit/2025-08-13https://www.hoparx.org/about-us/access-representation-opportunity-at-hopa/aro-toolkit/dei-toolkit-roadmap/2025-08-13https://www.hoparx.org/about-us/access-representation-opportunity-at-hopa/aro-toolkit/dei-toolkit-education-and-training/2025-08-13https://www.hoparx.org/about-us/access-representation-opportunity-at-hopa/aro-toolkit/dei-toolkit-patient-care-resources/2025-08-18https://www.hoparx.org/about-us/access-representation-opportunity-at-hopa/aro-toolkit/dei-toolkit-workplace/2025-08-13https://www.hoparx.org/about-us/access-representation-opportunity-at-hopa/aro-toolkit/dei-toolkit-research-disparities/2025-08-13https://www.hoparx.org/about-us/well-being-at-hopa/2025-06-04https://www.hoparx.org/about-us/well-being-at-hopa/wellness-toolkit/2025-02-25https://www.hoparx.org/about-us/well-being-at-hopa/wellness-toolkit/resident-early-career/2025-02-25https://www.hoparx.org/about-us/well-being-at-hopa/wellness-toolkit/established-career-mid-level/2025-02-25https://www.hoparx.org/about-us/well-being-at-hopa/wellness-toolkit/management-leadership-wellness-toolkit/2025-02-25https://www.hoparx.org/about-us/well-being-at-hopa/wellness-toolkit/podcast-wellness-resources/2025-02-25https://www.hoparx.org/about-us/hopa-publications/2026-04-01https://www.hoparx.org/about-us/hopa-publications/hopa-news/2025-10-03https://www.hoparx.org/about-us/hopa-publications/hopa-news-archives/2025-03-26https://www.hoparx.org/about-us/hopa-publications/jhop-journal-of-hematology-oncology-pharmacy/2026-03-12https://www.hoparx.org/about-us/hopa-publications/hopa-news-late-breaking-news/2025-11-26https://www.hoparx.org/about-us/hopa-publications/hopa-now-podcast/2026-03-10https://www.hoparx.org/about-us/hopa-publications/hopa-now-podcast/archive/2026-03-10https://www.hoparx.org/about-us/hopa-publications/member-submitted-papers/2026-03-19https://www.hoparx.org/about-us/hopa-publications/book-of-letters/2026-04-01https://www.hoparx.org/about-us/media-room/2025-11-19https://www.hoparx.org/about-us/media-room/member-interviews/2026-02-02https://www.hoparx.org/about-us/media-room/press-releases/2026-04-01https://www.hoparx.org/about-us/media-room/position-statements-issue-briefs/2026-01-28https://www.hoparx.org/about-us/media-room/sign-on-letters/2026-02-09https://www.hoparx.org/about-us/strategic-plan/2025-08-13https://www.hoparx.org/about-us/hopa-policies-disclaimers/2025-11-20https://www.hoparx.org/about-us/hopa-policies-disclaimers/hopa-privacy-policy/2025-11-20https://www.hoparx.org/about-us/waystogive/2026-03-18https://www.hoparx.org/about-us/contact-us/2024-03-26https://www.hoparx.org/hopa-learn/2026-04-01https://www.hoparx.org/hopa-learn/conferences-events/2026-03-30https://www.hoparx.org/hopa-learn/conferences-events/annual-conference/2026-04-01https://www.hoparx.org/hopa-learn/conferences-events/annual-conference/social-media-toolkit/2026-02-03https://www.hoparx.org/hopa-learn/conferences-events/call-for-abstracts/2026-01-27https://www.hoparx.org/hopa-learn/conferences-events/call-for-abstracts/late-breaking-research-abstracts/2025-11-11https://www.hoparx.org/hopa-learn/conferences-events/call-for-abstracts/completed-research-abstracts/2025-11-11https://www.hoparx.org/hopa-learn/conferences-events/call-for-abstracts/trainee-research-abstracts/2026-01-05https://www.hoparx.org/hopa-learn/conferences-events/call-for-abstracts/research-abstract-submission-faq/2024-11-27https://www.hoparx.org/hopa-learn/conferences-events/travel-grants/2026-01-19https://www.hoparx.org/hopa-learn/conferences-events/conference-buddies/2026-02-24https://www.hoparx.org/hopa-learn/conferences-events/wellness-webinar/2024-08-01https://www.hoparx.org/hopa-learn/conferences-events/wellness-webinar/clinican-well-being-on-demand-webinar/2024-08-01https://www.hoparx.org/hopa-learn/conferences-events/hopa-virtual-practice-management-series-main/2026-03-03https://www.hoparx.org/hopa-learn/conferences-events/call-for-presenters/2025-09-08https://www.hoparx.org/hopa-learn/curated-bcop-program/2026-01-22https://www.hoparx.org/hopa-learn/bcop-annual-conference-on-demand/2025-05-28https://www.hoparx.org/hopa-learn/bcop-annual-conference-on-demand/hopa-2025-complete-bundle-on-demand/2026-01-09https://www.hoparx.org/hopa-learn/bcop-annual-conference-on-demand/hopa-2025-bcop-only-bundle-on-demand/2026-01-09https://www.hoparx.org/hopa-learn/hopa-core-competency/2025-02-07https://www.hoparx.org/hopa-learn/hopa-core-competency/2023-core-competency-program-bundle-individual/2025-08-26https://www.hoparx.org/hopa-learn/hopa-core-competency/module-1-basic-oncology-pharmacology/2025-08-26https://www.hoparx.org/hopa-learn/hopa-core-competency/module-2-evaluation-of-chemotherapy-orders-and-initial-patient-assessment/2025-08-26https://www.hoparx.org/hopa-learn/hopa-core-competency/module-3-monitoring-and-modifying-cancer-treatment-care-plans/2025-08-26https://www.hoparx.org/hopa-learn/hopa-core-competency/module-4-calculating-appropriate-doses-of-anticancer-medications-for-hematologyoncology-patients/2025-08-26https://www.hoparx.org/hopa-learn/hopa-core-competency/module-5-effective-patient-education/2025-08-26https://www.hoparx.org/hopa-learn/hopa-core-competency/module-6-designing-and-implementing-supportive-care-plans/2025-08-26https://www.hoparx.org/hopa-learn/hopa-core-competency/module-7-extravasation-when-chemotherapy-misses-the-mark/2025-08-26https://www.hoparx.org/hopa-learn/hopa-core-competency/module-8-value-based-frameworks-in-oncology/2025-08-26https://www.hoparx.org/hopa-learn/hopa-core-competency/module-9-medication-procurement/2025-08-26https://www.hoparx.org/hopa-learn/hopa-core-competency/module-10-billing-and-reimbursement/2025-08-26https://www.hoparx.org/hopa-learn/hopa-core-competency/module-11-safe-handling-of-hazardous-drugs/2025-08-26https://www.hoparx.org/hopa-learn/hopa-core-competency/module-12-investigational-drug-principles/2025-08-26https://www.hoparx.org/hopa-learn/core-competency-program/2026-03-05https://www.hoparx.org/hopa-learn/bcop-prep-recert/2025-10-14https://www.hoparx.org/hopa-learn/bcop-prep-recert/bcop-preparatory-course-acpe-credits-only/2026-01-09https://www.hoparx.org/hopa-learn/bcop-prep-recert/bcop-recertification-course/2026-01-09https://www.hoparx.org/hopa-learn/bcop-self-study/2025-09-08https://www.hoparx.org/hopa-learn/bcop-self-study/self-study-2025-release-ii-bundle/2026-01-09https://www.hoparx.org/hopa-learn/bcop-self-study/release-ii-2025-review-of-cns-prophylaxis-in-adult-hematologic-malignancies/2026-01-09https://www.hoparx.org/hopa-learn/bcop-self-study/release-ii-2025-gene-therapy-advances-in-hemophilia-sickle-cell-beta-thalassemia/2026-01-09https://www.hoparx.org/hopa-learn/bcop-self-study/release-ii-2025-the-four-body-problem-four-drug-regimens-in-newly-diagnosed-multiple-myeloma/2026-01-09https://www.hoparx.org/hopa-learn/bcop-self-study/release-ii-2025-updates-in-the-treatment-of-hormone-receptor-positive-metastatic-breast-cancer/2026-01-09https://www.hoparx.org/hopa-learn/bcop-self-study/release-ii-2025-antibody-drug-conjugates-in-solid-tumors/2026-01-09https://www.hoparx.org/hopa-learn/bcop-self-study/self-study-2025-release-i-bundle/2026-01-09https://www.hoparx.org/hopa-learn/bcop-self-study/release-i-2025-treatment-of-non-melanoma-skin-cancers/2026-01-09https://www.hoparx.org/hopa-learn/bcop-self-study/release-i-2025-anxiety-and-depression-in-adult-survivors-of-cancer/2026-01-09https://www.hoparx.org/hopa-learn/bcop-self-study/release-i-2025-targeting-her2-in-non-breast-solid-tumors/2026-01-09https://www.hoparx.org/hopa-learn/bcop-self-study/release-i-2025-germline-genetic-testing-in-patients-with-cancer/2026-01-09https://www.hoparx.org/hopa-learn/bcop-self-study/release-i-2025-myeloproliferative-neoplasms-a-focus-on-jak-inhibitors-in-myelofibrosis/2026-01-09https://www.hoparx.org/hopa-learn/bcop-updates/2025-07-19https://www.hoparx.org/hopa-learn/bcop-updates/2025-a-joint-effort-managing-safe-medical-marijuana-use-in-oncology-patients/2026-01-09https://www.hoparx.org/hopa-learn/bcop-updates/2025-hope-for-a-generation-recent-advancements-in-sickle-cell-disease/2026-01-09https://www.hoparx.org/hopa-learn/bcop-updates/using-cystatin-c-to-evaluate-kidney-dysfunction-in-patients-with-malignancy-and-caring-for-pregnant-patients-with-malignancy/2026-01-09https://www.hoparx.org/hopa-learn/bcop-updates/becoming-comfortable-in-the-gray-gy-radiation-oncology-for-pharmacists/2026-01-12https://www.hoparx.org/hopa-learn/bcop-updates/updates-in-upper-gi-cancers/2026-01-09https://www.hoparx.org/hopa-learn/bcop-updates/the-beans-are-making-a-scene-updates-in-renal-cell-carcinoma/2026-01-09https://www.hoparx.org/hopa-learn/bcop-updates/updates-in-carcinoma-of-unknown-primary/2026-01-09https://www.hoparx.org/hopa-learn/bcop-updates/bcop-updates-2025-bundle/2026-01-09https://www.hoparx.org/hopa-learn/journal-club/2026-03-17https://www.hoparx.org/hopa-learn/project-livin-label/2023-12-14https://www.hoparx.org/hopa-learn/project-livin-label/project-livin-label-episode-8/2025-08-26https://www.hoparx.org/hopa-learn/project-livin-label/project-livin-label-episode-9/2025-08-26https://www.hoparx.org/hopa-learn/project-livin-label/episode-10-ivosidenib-the-backstory/2025-08-26https://www.hoparx.org/hopa-learn/project-livin-label/episode-11-fam-trastuzumab-deruxtecan-nxki-the-backstory/2025-08-26https://www.hoparx.org/hopa-learn/bcop-recertification-chapters/2025-10-14https://www.hoparx.org/hopa-learn/bcop-recertification-chapters/bcop-recertification-chapters-solids-and-heme/2026-01-09https://www.hoparx.org/hopa-learn/bcop-recertification-chapters/bcop-recertification-chapters-solids-only/2026-01-09https://www.hoparx.org/hopa-learn/bcop-recertification-chapters/bcop-recertification-chapters-heme-only/2026-01-09https://www.hoparx.org/hopa-learn/ons-til-therapy-webinar/2025-08-26https://www.hoparx.org/hopa-learn/hopa-oncology-case-series/2026-02-25https://www.hoparx.org/hopa-learn/hopa-virtual-practice-management-series-courses/2026-03-03https://www.hoparx.org/hopa-learn/hopa-virtual-practice-management-series-courses/bridging-the-gap-managing-transitions-of-care-for-complex-therapies/2026-01-26https://www.hoparx.org/hopa-learn/hopa-virtual-practice-management-series-courses/optimizing-oncology-stewardship-on-demand/2026-01-09https://www.hoparx.org/hopa-learn/hopa-virtual-practice-management-series-courses/the-safety-net-pharmacists-stewards-of-medication-safety-on-demand/2026-01-09https://www.hoparx.org/hopa-learn/hopa-virtual-practice-management-series-courses/practice-management-data-for-current-oncology-pharmacy-practice-on-demand/2026-01-09https://www.hoparx.org/hopa-learn/hopa-virtual-practice-management-series-courses/practice-management-designing-comprehensive-symptom-management-pathways-on-demand/2026-01-12https://www.hoparx.org/hopa-learn/hoparxorgcancer-drug-repositories/2025-10-16https://www.hoparx.org/hopa-learn/avaho-bcop-preconference/2025-11-10https://www.hoparx.org/hopa-learn/avaho-bcop-preconference/oncology-pharmacy-in-focus/2026-01-09https://www.hoparx.org/membership/2025-09-15https://www.hoparx.org/membership/become-a-member/2026-03-18https://www.hoparx.org/membership/become-a-member/hopa-membership-drive/2024-10-02https://www.hoparx.org/membership/mentorship-program/2026-02-10https://www.hoparx.org/membership/mentorship-program/mentors-mentees/2026-02-10https://www.hoparx.org/membership/hopa-ambassadors/2025-07-22https://www.hoparx.org/membership/hopa-ambassadors/lisa-holle-pharmd-bcop-fhopa-fisopp/2023-10-06https://www.hoparx.org/membership/hopa-ambassadors/david-deremerpharmd-bcop-fccp-fhopa/2023-10-06https://www.hoparx.org/membership/hopa-ambassadors/amanda-seddon/2023-10-06https://www.hoparx.org/membership/hopa-ambassadors/karen-fancher-pharmd-bcop/2025-07-22https://www.hoparx.org/membership/volunteer-activity-center/2026-03-17https://www.hoparx.org/membership/volunteer-activity-center/year-round-volunteer-opportunities/2026-04-01https://www.hoparx.org/membership/volunteer-activity-center/authors-reviewers/2025-07-09https://www.hoparx.org/membership/volunteer-activity-center/bps-pain-management-standard-setting-panel/2025-09-08https://www.hoparx.org/membership/volunteer-activity-center/cancer-guideline-updates-commentary/2026-03-10https://www.hoparx.org/membership/membership-spotlight/2024-07-17https://www.hoparx.org/membership/membership-spotlight/member-spotlight-aseala-abousaud-pharmd-bcop/2023-06-28https://www.hoparx.org/membership/membership-spotlight/member-spotlight-jordyn-paige-higgins-pharmd-bcop/2024-07-17https://www.hoparx.org/membership/membership-spotlight/member-spotlight-jennifer-thackray-pharmd-bcps-bcpps/2023-06-28https://www.hoparx.org/membership/membership-spotlight/member-spotlight-katie-gatwood-pharmd-bcop/2023-06-28https://www.hoparx.org/membership/membership-spotlight/member-spotlight-bernard-marini-pharmd-bcop/2023-06-28https://www.hoparx.org/membership/membership-spotlight/member-spotlight-nicole-a-brunette-pharmd-bcps-bcop/2023-09-28https://www.hoparx.org/membership/membership-spotlight/vivian-loo-pharmd-bcop/2024-02-14https://www.hoparx.org/membership/membership-spotlight/member-spotlight-jordan-hill-pharmd-bcop/2024-07-17https://www.hoparx.org/membership/oncology-special-interest-groups-sigs/2026-02-12https://www.hoparx.org/membership/oncology-special-interest-groups-sigs/virtual-oncology-roundtable/2025-04-23https://www.hoparx.org/membership/elections/2026-03-10https://www.hoparx.org/membership/hopas-leadership-corner/2026-01-20https://www.hoparx.org/membership/hopas-leadership-corner/leadership-spotlight/2025-06-09https://www.hoparx.org/membership/hopas-leadership-corner/leadership-spotlight/john-g-kuhn/2023-10-04https://www.hoparx.org/membership/hopas-leadership-corner/leadership-spotlight/rowena-moe-schwartz/2024-01-05https://www.hoparx.org/membership/hopas-leadership-corner/leadership-spotlight/chris-fausel/2025-06-09https://www.hoparx.org/membership/hopas-leadership-corner/leadership-spotlight/jessica-auten/2025-06-09https://www.hoparx.org/membership/hopas-leadership-corner/resources/2023-06-21https://www.hoparx.org/membership/hopa-bylaw-updates-2023/2024-06-18https://www.hoparx.org/membership/awards-and-recognition/2026-04-02https://www.hoparx.org/membership/awards-and-recognition/member-awards-nominations/2025-10-06https://www.hoparx.org/membership/awards-and-recognition/hopa-fellow-nominations/2025-10-06https://www.hoparx.org/membership/awards-and-recognition/hopa-member-award-winners/2026-04-02https://www.hoparx.org/membership/awards-and-recognition/hopa-fellows/2026-04-02https://www.hoparx.org/membership/member-toolkit/2024-04-23https://www.hoparx.org/membership/regional-networking-events/2025-10-30https://www.hoparx.org/membership/hoparxorgresident-pathways/2025-11-05https://www.hoparx.org/resources/2026-02-25https://www.hoparx.org/resources/clinical-trials/2025-07-22https://www.hoparx.org/resources/drug-updates/2023-12-01https://www.hoparx.org/resources/hopa-oral-chemotherapy-collaborative-occtm/2026-02-17https://www.hoparx.org/resources/professional-tools/2025-01-03https://www.hoparx.org/resources/oncology-quality-resources/2025-10-06https://www.hoparx.org/resources/oncology-quality-resources/what-is-quality/2025-08-06https://www.hoparx.org/resources/oncology-quality-resources/quality-training/2026-03-24https://www.hoparx.org/resources/oncology-quality-resources/quality-tools/2024-05-21https://www.hoparx.org/resources/research/2026-04-01https://www.hoparx.org/resources/research/research-grants-faqs/2024-04-29https://www.hoparx.org/resources/research/research-grantees/2025-03-10https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/2026-02-03https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/highlights-from-academy-of-managed-care-pharmacy-amcp-nexus-2022/2023-03-09https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/highlights-from-american-association-of-colleges-of-pharmacy-aacp-annual-meeting-2022/2023-03-09https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/highlights-from-the-2022-national-community-oncology-dispensing-organization-ncoda-spring-forum/2023-03-09https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/welcome-back-to-mccormick-highlights-from-the-2022-american-society-of-clinical-oncology-annual-meeting/2023-03-09https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/summaries-of-allied-organization-meetings/2023-03-09https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/highlights-of-the-jadpro-live-2021-educational-conference/2023-03-09https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/highlights-from-the-2021-national-community-oncology-dispensing-association-ncoda-professional-student-organization-pso-annual-meeting/2023-03-09https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/highlights-from-2020-american-society-of-clinical-oncology-virtual-scientific-program/2023-03-09https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/highlights-from-the-2020-transplantation-and-cellular-therapy-meetings-of-the-american-society-for-blood-and-marrow-transplantation-and-the-center-for-international-blood-and-marrow-transplant-research/2023-03-09https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/2022-american-society-of-hematology-ash-annual-meeting/2023-03-09https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/international-society-of-liquid-biopsy-annual-congress-2022/2023-03-09https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/2023-tandem-meetings-transplantation-cellular-therapy-meetings-of-astct-and-cibmtr/2024-02-26https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/2023-tandem-meetings-connecting-at-the-crossroads-when-provider-and-patient-paths-converge/2024-02-26https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/american-society-of-hematology-2023-annual-meeting/2024-04-22https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/2024-tandem-meetings-transplantation-cellular-therapy-meetings-of-astct-and-cibmtr/2024-06-13https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/2024-asco-annual-meeting/2024-06-24https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/2025-tandem-meetings-summary/2025-03-21https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/opc-2025/2025-10-23https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/2025-atopp-summit-summary/2025-11-21https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/2025-ash-annual-meeting/2026-01-29https://www.hoparx.org/resources/summaries-of-allied-organization-meetings/amcp-nexus-2025/2026-02-03https://www.hoparx.org/resources/coronavirus-covid-191/2023-02-06https://www.hoparx.org/resources/chemotherapy-education/2023-09-22https://www.hoparx.org/resources/guidelines-standards-and-summaries/2025-11-25https://www.hoparx.org/resources/pharmacists-application-to-practice/2026-03-11https://www.hoparx.org/resources/anemia-management-for-mds-patients/2024-09-11https://www.hoparx.org/resources/student-engagement-program/2025-12-09https://www.hoparx.org/resources/student-engagement-program/student-engagement-program-access-form/2025-08-27https://www.hoparx.org/resources/irb-process-webinar/2025-10-21https://www.hoparx.org/resources/precision-oncology-initiative/2026-01-21https://www.hoparx.org/resources/precision-oncology-initiative/qtp-6-month-precision-oncology-program/2026-01-08https://www.hoparx.org/resources/cpd-resources/2026-03-23https://www.hoparx.org/support/2025-10-15https://www.hoparx.org/support/industry-relations-council/2024-08-26https://www.hoparx.org/support/industry-relations-council/irc-participants/2026-02-24https://www.hoparx.org/support/exhibitor-information/2025-12-03https://www.hoparx.org/support/partnership-opportunities/2026-02-10https://www.hoparx.org/patient-education/2026-03-05https://www.hoparx.org/patient-education/clinical-trials/2026-01-28https://www.hoparx.org/patient-education/chemotherapy-induced-nausea-and-vomiting-cinv-time-to-talk/2024-09-20https://www.hoparx.org/patient-education/time-to-talk-immune-checkpoint-inhibitors/2024-10-03https://www.hoparx.org/patient-education/time-to-talk-cellular-therapy/2025-07-08https://www.hoparx.org/patient-education/time-to-talk-to-your-oncology-pharmacist/2024-09-13https://www.hoparx.org/patient-education/patient-assistance-programs/2026-02-02https://www.hoparx.org/patient-education/estudios-clinicos/2025-08-19https://www.hoparx.org/patient-education/patient-education-sheets/2025-10-03https://www.hoparx.org/latest-news/2026-03-17https://www.hoparx.org/latest-news/role-of-pharmacist/2023-01-09https://www.hoparx.org/latest-news/covid-19-health-equity-task-force/2023-01-30https://www.hoparx.org/latest-news/vaccine-distribution-guidelines/2022-11-17https://www.hoparx.org/latest-news/value-of-oncology-pharmacists/2023-01-31https://www.hoparx.org/latest-news/president-brings-unique-perspective/2024-04-22https://www.hoparx.org/latest-news/Release-Online-IV-Cancer/2023-09-22https://www.hoparx.org/latest-news/journal-of-hematology-oncology-pharmacy-named-official-publication-of-the-hematologyoncology-pharmacy-association/2023-02-01https://www.hoparx.org/latest-news/tracelyn-freeman-recipient-of-hopas-top-10-trainee-research-award/2023-02-01https://www.hoparx.org/latest-news/hopa-launches-new-oncology-pharmacy-certificate-program/2023-09-22https://www.hoparx.org/latest-news/available-now-new-toolkit-encourages-better-communication-to-help-prevent-patients-from-suffering-in-silence-due-to-chemotherapy-induced-nausea-and-vomiting/2023-02-01https://www.hoparx.org/latest-news/overcoming-challenges-to-provide-bite-and-car-t-cell-therapy-at-a-community-cancer-center/2025-05-08https://www.hoparx.org/latest-news/reaching-the-melting-point-my-time-transitioning-from-a-solid-to-a-liquid-tumor-pharmacist/2023-03-22https://www.hoparx.org/latest-news/is-colonoscopy-here-to-stay-evaluation-of-average-risk-colorectal-cancer-screening-updates-review-of-nordicc/2024-02-04https://www.hoparx.org/latest-news/bps-announcement/2023-08-03https://www.hoparx.org/latest-news/adapting-investigational-drug-services-during-a-pandemic/2024-09-19https://www.hoparx.org/latest-news/reflections-from-a-life-long-oncology-pharmacist-unconditional-care/2023-05-17https://www.hoparx.org/latest-news/immune-checkpoint-inhibitors-make-great-strides-in-hepatocellular-carcinoma/2023-07-06https://www.hoparx.org/latest-news/oncology-experts-join-together-to-provide-best-possible-care-for-adolescents-and-young-adults-with-cancer/2023-06-30https://www.hoparx.org/latest-news/drug-shortages-issue-brief/2024-09-09https://www.hoparx.org/latest-news/hopas-drug-shortages-survey-findings/2024-09-09https://www.hoparx.org/latest-news/nationwide-oncology-landscape-survey-findings/2024-09-09https://www.hoparx.org/latest-news/collaboration-to-improve-treatment-of-myelodysplastic-syndromes-in-adults/2023-06-30https://www.hoparx.org/latest-news/two-trials-to-change-the-landscape-for-first-line-treatment-for-advanced-or-recurrent-endometrial-cancer/2024-02-04https://www.hoparx.org/latest-news/2023-tandem-meetings-transplantation-cellular-therapy-meetings-of-astct-and-cibmtr/2024-09-09https://www.hoparx.org/latest-news/pharmacists-application-to-practice-tremelimumab/2024-03-27https://www.hoparx.org/latest-news/pharmacists-application-to-practice-pirtobrutinib/2024-09-20https://www.hoparx.org/latest-news/pharmacists-applications-to-practice-elacestrant/2024-03-21https://www.hoparx.org/latest-news/pharmacists-applications-to-practice-retifanlimab-dlwr/2023-10-16https://www.hoparx.org/latest-news/pharmacist-application-to-practice-adagrasib/2024-03-27https://www.hoparx.org/latest-news/pharmacists-application-to-practice-futibatinib/2024-03-21https://www.hoparx.org/latest-news/pharmacists-application-to-practice-mirvetuximab-soravtansine-gynx/2024-03-27https://www.hoparx.org/latest-news/pharmacists-application-to-practice-mosunetuzumab/2023-09-28https://www.hoparx.org/latest-news/pharmacists-application-to-practice-nadofaragene-firadenovec-vncg/2024-03-26https://www.hoparx.org/latest-news/pharmacists-application-to-practice-olutasidenib/2024-09-09https://www.hoparx.org/latest-news/pharmacists-application-to-practice-teclistamab-cqyv/2024-03-27https://www.hoparx.org/latest-news/hopa-partners-with-pqa/2023-10-05https://www.hoparx.org/latest-news/3-feature-indication-withdrawals-of-small-molecule-inhibitors-from-the-accelerated-approval-program/2023-10-18https://www.hoparx.org/latest-news/hopas-statement-of-pharmacists-suppoort/2023-10-30https://www.hoparx.org/latest-news/pharmacists-application-to-practice-elranatamab-bcmm/2024-09-09https://www.hoparx.org/latest-news/pharmacists-application-to-practice-glofitamab/2023-11-06https://www.hoparx.org/latest-news/pharmacists-application-to-practice-quizartinib/2023-11-06https://www.hoparx.org/latest-news/genitourinary-updates-from-esmo-2023/2024-02-04https://www.hoparx.org/latest-news/pharmacists-application-to-practice-fruquintinib/2024-03-21https://www.hoparx.org/latest-news/pharmacists-application-to-practice-niraparib-and-abiraterone-acetate-akeega/2024-09-09https://www.hoparx.org/latest-news/pharmacists-application-to-practice-epcoritamab-bysp/2024-09-09https://www.hoparx.org/latest-news/pharmacists-application-to-practice-talquetamab-tgvs/2024-09-09https://www.hoparx.org/latest-news/pharmacists-application-to-practice-momelotinib/2024-03-21https://www.hoparx.org/latest-news/pharmacists-application-to-practice-hepzato-kit/2024-02-01https://www.hoparx.org/latest-news/pharmacists-applications-to-practice-repotrectinib/2024-03-27https://www.hoparx.org/latest-news/amivantamab-plus-chemotherapy-with-and-without-lazertinib-in-egfr-mutant-advanced-nsclc-after-disease-progression-on-osimertinib-primary-results-from-the-phase-iii-mariposa-2-study/2024-02-09https://www.hoparx.org/latest-news/taking-commands-of-myelodysplastic-syndrome-related-anemia-management-with-luspatercept-aamt/2024-02-05https://www.hoparx.org/latest-news/osimertinib-with-or-without-chemotherapy-in-egfr-mutated-advanced-nsclc/2024-02-09https://www.hoparx.org/latest-news/axicabtagene-ciloleucel-as-second-line-therapy-for-large-b-cell-lymphoma/2024-02-09https://www.hoparx.org/latest-news/talazoparib-plus-enzalutamide-in-men-with-first-line-metastatic-castration-resistant-prostate-cancer-talapro-2-a-randomised-placebo-controlled-phase-3-trial/2024-02-09https://www.hoparx.org/latest-news/trifluridinetipiracil-and-bevacizumab-in-refractory-metastatic-colorectal-cancer/2024-02-09https://www.hoparx.org/latest-news/elranatamab-in-relapsed-or-refractory-multiple-myeloma-phase-2-magnetismm-3-trial-results/2024-02-09https://www.hoparx.org/latest-news/pirtobrutinib-in-covalent-bruton-tyrosine-kinase-inhibitor-pretreated-mantle-cell-lymphoma/2024-02-09https://www.hoparx.org/latest-news/post-transplantation-cyclophosphamide-based-graft-versus-host-disease-prophylaxis/2024-02-09https://www.hoparx.org/latest-news/capivasertib-in-hormone-receptorpositive-advanced-breast-cancer/2024-02-09https://www.hoparx.org/latest-news/hopa-and-cancer-support-community-bring-together-patient-and-pharmacist-points-of-view/2024-02-19https://www.hoparx.org/latest-news/cilta-cel-or-standard-care-in-lenalidomide-refractory-multiple-myeloma/2024-02-14https://www.hoparx.org/latest-news/dabrafenib-plus-trametinib-in-pediatric-glioma-with-braf-v600-mutations/2024-02-14https://www.hoparx.org/latest-news/efficacy-and-safety-of-pembrolizumab-in-combination-with-bevacizumab-and-oral-metronomic-cyclophosphamide-in-the-treatment-of-recurrent-ovarian-cancer/2024-03-07https://www.hoparx.org/latest-news/olutasidenib-alone-or-with-azacitidine-in-idh1-mutated-acute-myeloid-leukaemia-and-myelodysplastic-syndrome-phase-1-results-of-a-phase-12-trial/2024-03-07https://www.hoparx.org/latest-news/tremelimumab-plus-durvalumab-in-unresectable-hepatocellular-carcinoma/2024-03-07https://www.hoparx.org/latest-news/combating-indigenous-health-disparties-amid-cancer-treatment/2025-03-07https://www.hoparx.org/latest-news/pharmacistss-application-to-practice-capivasertib/2024-03-27https://www.hoparx.org/latest-news/pharmacists-applications-to-practice-eflornithine-for-high-risk-neuroblastoma/2024-03-27https://www.hoparx.org/latest-news/pharmacists-applications-to-practice-nirogacestat-ogsiveo/2024-03-27https://www.hoparx.org/latest-news/late-breaking-hopa-news-t-cell-malignancies-with-car-t-cell-therapy/2024-09-09https://www.hoparx.org/latest-news/standardization-of-ids-key-performance-indicators-and-metrics/2024-04-12https://www.hoparx.org/latest-news/hopa-president-committed-to-direct-patient-care-especially-for-veterans-with-cancer/2024-04-30https://www.hoparx.org/latest-news/hopas-conference-a-notable-event-for-tampa-convention-center/2024-04-22https://www.hoparx.org/latest-news/late-breaking-hopa-news-severe-hypocalcemia-in-patients-with-advanced-chronic-kidney-disease-on-denosumab-therapy/2024-09-09https://www.hoparx.org/latest-news/pharmacists-patients-lend-their-voices-to-virtual-hill-day/2024-09-09https://www.hoparx.org/latest-news/pharmacists-application-to-practice-tislelizumab-jsgr/2024-09-09https://www.hoparx.org/latest-news/late-breaking-hopa-news-adjuvant-alectinib-in-early-stage-non-small-cell-lung-cancer-nsclc/2024-09-09https://www.hoparx.org/latest-news/the-many-layers-of-bipoc-underrepresentation-in-cancer-clinical-trials/2025-03-07https://www.hoparx.org/latest-news/late-breaking-hopa-news-car-t-approval-updates/2024-07-22https://www.hoparx.org/latest-news/pharmacists-application-to-practice-nogapendekin-alfa-inbakicept-pmln/2024-08-27https://www.hoparx.org/latest-news/oncology-pharmacy-staffing-survey-across-practice-settings-in-the-united-states/2024-09-19https://www.hoparx.org/latest-news/clinical-oncology-pharmacy-technician-impact-of-a-new-role-on-pharmacy-and-patient-metrics-at-a-large-academic-cancer-center/2024-09-20https://www.hoparx.org/latest-news/pharmacists-application-to-practice-imetelstat/2024-10-16https://www.hoparx.org/latest-news/pharmacists-application-to-practice-tarlatamab-dlle/2024-10-16https://www.hoparx.org/latest-news/pharmacists-application-to-practice-afamitresgene-autoleucel/2024-10-16https://www.hoparx.org/latest-news/pharmacists-application-to-practice-axatilimab-csfr/2024-10-16https://www.hoparx.org/latest-news/hopa-and-cmrignite-launch-time-to-talk-diversity-in-clinical-trials-campaign/2024-11-06https://www.hoparx.org/latest-news/oncology-stewardship-practice-in-the-united-states-a-hematologyoncology-pharmacy-association-national-survey/2024-11-26https://www.hoparx.org/latest-news/pharmacists-application-to-practice-inavolisib/2024-11-27https://www.hoparx.org/latest-news/pharmacists-application-to-practice-vorasidenib/2024-11-27https://www.hoparx.org/latest-news/pharmacists-application-to-practice-zolbetuximab-clzb/2024-12-16https://www.hoparx.org/latest-news/pharmacists-application-to-practice-sacituzumab-govitecan-hziy/2025-03-05https://www.hoparx.org/latest-news/late-breaking-hopa-news-navigating-the-nationwide-iv-fluid-shortage-and-its-toll-on-oncology-care/2024-12-19https://www.hoparx.org/latest-news/late-breaking-hopa-news-ribociclib-in-the-adjuvant-setting-breast-cancer/2024-12-23https://www.hoparx.org/latest-news/late-breaking-hopa-news-how-low-can-you-go-fam-trastuzumab-deruxtecan-nxki/2025-01-10https://www.hoparx.org/latest-news/development-and-implementation-of-oral-anticancer-agent-tools-for-a-thematic-quality-improvement-program/2025-02-04https://www.hoparx.org/latest-news/hopa-bone-marrow-cancer-foundation-and-walgreens-specialty-unite-to-provide-oncology-pharmacy-education/2025-02-07https://www.hoparx.org/latest-news/message-to-members-during-unprecedented-times/2025-02-11https://www.hoparx.org/latest-news/hopa-supports-life-saving-cancer-research/2025-05-21https://www.hoparx.org/latest-news/pharmacists-application-to-practice-zenocutuzumab-zbco/2025-03-05https://www.hoparx.org/latest-news/pharmacists-application-to-practice-cosibelimab-ipdl/2025-03-10https://www.hoparx.org/latest-news/pharmacists-application-to-practice-revumenib/2025-03-12https://www.hoparx.org/latest-news/pharmacists-application-to-practice-datopotamab-deruxtecan-dlnk/2025-03-13https://www.hoparx.org/latest-news/pharmacists-application-to-practice-ensartinib/2025-03-17https://www.hoparx.org/latest-news/pharmacists-application-to-practice-mirdametinib/2025-04-08https://www.hoparx.org/latest-news/hopa-president-combines-people-first-approach-with-oncology-pharmacy-expertise/2025-04-22https://www.hoparx.org/latest-news/late-breaking-hopa-news-the-emerging-use-of-bispecific-antibodies-with-chemotherapy-in-diffuse-large-b-cell-lymphoma/2025-04-29https://www.hoparx.org/latest-news/pharmacists-application-to-practice-remestemcel-l-rknd/2025-05-06https://www.hoparx.org/latest-news/late-breaking-hopa-news-ai-integration-in-pharmacy/2025-05-07https://www.hoparx.org/latest-news/hopa-annual-conference-2025-sets-attendance-record/2025-05-12https://www.hoparx.org/latest-news/powering-through-uncertainty-and-doubt-my-journey-as-a-non-traditional-pgy2-oncology-resident/2025-05-14https://www.hoparx.org/latest-news/time-to-complete-oncology-pharmacist-tasks-research-statement/2025-06-23https://www.hoparx.org/latest-news/federal-spending-cuts-campaign/2025-05-27https://www.hoparx.org/latest-news/asco-2025-recap/2025-06-05https://www.hoparx.org/latest-news/hopa-signs-letters-supporting-medicaid-nih-against-funding-cuts/2025-07-02https://www.hoparx.org/latest-news/no-higher-calling-reflections-on-a-career-in-higher-education/2025-07-10https://www.hoparx.org/latest-news/cancer-drug-parity-act-reintroduction/2025-07-14https://www.hoparx.org/latest-news/hopa-and-avaho-bcop-partnership/2025-08-27https://www.hoparx.org/latest-news/role-of-ids-pharmacy-technicians/2025-08-12https://www.hoparx.org/latest-news/hopa-joins-ashp-your-pharmacist-campaign/2025-10-01https://www.hoparx.org/latest-news/responsible-use-of-leucovorin/2025-09-25https://www.hoparx.org/latest-news/late-breaking-hopa-news-adding-maintenance-chemotherapy-to-maintenance-immunotherapy/2025-09-29https://www.hoparx.org/latest-news/new-patient-education-sheets/2025-10-03https://www.hoparx.org/latest-news/record-breaking-hill-day-participation-brings-hopa-advocacy-education-to-dc/2025-10-06https://www.hoparx.org/latest-news/a-journey-of-a-thousand-miles-begins-navigating-the-path-to-a-leadership-position/2025-10-10https://www.hoparx.org/latest-news/government-shutdown-2025/2025-10-23https://www.hoparx.org/latest-news/hopa-supports-fda-box-label-changes-for-dpyd-testing/2025-10-24https://www.hoparx.org/latest-news/quality-and-equity-in-cancer-care/2025-11-11https://www.hoparx.org/latest-news/2025-us-government-shutdown-update/2025-11-14https://www.hoparx.org/latest-news/late-breaking-hopa-news-the-evolving-landscape-of-npm1-mutated-aml/2025-11-26https://www.hoparx.org/latest-news/pharmacists-application-to-practice-linvoseltamab-gcpt/2025-12-10https://www.hoparx.org/latest-news/late-breaking-hopa-news-belantamab-mafodotin-bmlf-returns-fda-restores-bcma-targeted-adc-option-for-rrmm/2025-12-22https://www.hoparx.org/latest-news/podcast-reflection-family-life-work-life-balance/2026-01-12https://www.hoparx.org/latest-news/pharmacists-application-to-practice-obecabtagene-autoleucel/2026-01-02https://www.hoparx.org/latest-news/2025-hopa-year-in-review/2026-01-22https://www.hoparx.org/latest-news/pharmacists-application-to-practice-dordaviprone/2026-01-02https://www.hoparx.org/latest-news/the-impacts-of-strong-professional-relationships-between-clinical-pharmacists-and-medical-science-liaisons/2026-01-06https://www.hoparx.org/latest-news/podcast-reflection-work-life-family-harmony/2026-01-19https://www.hoparx.org/latest-news/pharmacists-application-to-practice-imlunestrant/2026-01-20https://www.hoparx.org/latest-news/proposed-student-loan-limits-hurt-healthcare/2026-01-28https://www.hoparx.org/latest-news/late-breaking-hopa-news-neoadaura-advancing-neoadjuvant-osimertinib-for-resectable-egfr-mutated-nsclc/2026-01-26https://www.hoparx.org/latest-news/pharmacists-application-to-practice-zongertinib/2026-01-28https://www.hoparx.org/latest-news/pharmacists-application-to-practice-taletrectinib/2026-03-03https://www.hoparx.org/latest-news/fiscal-year-2026-funding-passes-update/2026-02-09https://www.hoparx.org/latest-news/snpha-hopa-cancer-clarity-challenge-press-release/2026-02-24https://www.hoparx.org/latest-news/pharmacists-application-to-practice-pirtobrutinib-for-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/2026-03-11https://www.hoparx.org/latest-news/late-breaking-hopa-news-what-majestec-3-means-for-the-treatment-of-multiple-myeloma/2026-03-17https://www.hoparx.org/latest-news/oncology-pharmacist-day/2026-04-01https://www.hoparx.org/hopa-store/2024-07-10https://www.hoparx.org/hopa-poster-for-asco-quality-symposium/2023-10-06https://www.hoparx.org/thebigidea/2025-05-30https://www.hoparx.org/thebigidea/the-big-idea-faqs/2024-10-01https://www.hoparx.org/thebigidea/the-big-idea-submission-guidelines/2024-09-13https://www.hoparx.org/thebigidea/inspiration/2024-06-24https://www.hoparx.org/thebigidea/big-idea-strategic-resources/2024-06-24